KETEK
LOE ApproachingNDAORALTABLET
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KETEK (telithromycin) is an oral ketolide antibiotic approved in 2004 for community-acquired pneumonia of mild to moderate severity, including multi-drug resistant Streptococcus pneumoniae. It works by inhibiting bacterial protein synthesis and achieves rapid absorption with peak plasma concentrations within 1 hour, followed by distribution to respiratory tissues including bronchial mucosa, epithelial lining fluid, and alveolar macrophages.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job activity, suggesting reduced commercial investment and team contraction.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Ketek in CAP / AECB in Ambulatory Adult Patients
Started May 2004
174 enrolled
Community Acquired Pneumonia (CAP)Acute Exacerbation of Chronic Bronchitis (AECB)
AMS VS MOXI Ketek vs Avelox in AMS
Started Dec 2002
351 enrolled
Maxillary Sinusitis
Career Relevance
With zero linked job openings and an LOE-approaching lifecycle, KETEK offers minimal career growth or advancement opportunities. This product is in wind-down mode, making it an unattractive career destination unless you seek niche expertise in antibiotic stewardship or legacy portfolio management.
Brand Manager
Worked on KETEK at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.